Post a Free Blog

Submit A Press Release

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Truck Series (TRUCK)
Ultimate Fighting Championship (UFC)
Uncategorized
US
Valorant
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
0
-- Advertisement --spot_img
HomeBusinessModerna’s Product Sales Beat Expectations

Moderna’s Product Sales Beat Expectations

Add to Favorite
Added to Favorite


Moderna (NASDAQ:MRNA) released its 2023 product sales figures, which exceeded analysts’ expectations.
The biotechnology company reported unaudited product sales of about $6.7 billion for the year, surpassing the consensus forecast of $6.38 billion. A significant development for Moderna was the increase in its U.S. market share for COVID-19 vaccines, which climbed to 48% in 2023, up from 37% the previous year.
Looking ahead, Moderna maintained its forecast for product sales of around $4 billion in 2024, with an aim to return to sales growth in 2025. The company is targeting a break-even point in 2026, which it plans to achieve through a mix of new product launches and judicious investment strategies.
Further underscoring its ongoing innovation, Moderna pointed to nine late-stage programs in its pipeline, with key milestones expected in 2024 and 2025.
In its financial outlook for 2024-2026, Moderna laid out plans indicating a path to profitability for its COVID-19 vaccine portfolio, with a specific goal of reaching break-even by 2026.

Subscribe to get Latest News Updates

Latest News

You may like more
more

Goldman Sachs BDC Struggles Amidst High Dividend Yield and Credit Challenges

Goldman Sachs BDC (GSBD:NYSE) Navigates Challenging Landscape Goldman Sachs BDC...

Ford Motor Company: A Strategic Investment in the EV Market

Ford Motor Company: A Value Investment in the Electric...

GSK (GSK:NYSE): A Promising Growth Stock for Long-Term Investors

GSK (GSK:NYSE): A Promising Growth Stock for Long-Term Investors GSK...

Olympic Steel, Inc. (ZEUS) Q1 2024 Earnings: Strategic Successes Amid Market Fluctuations

Olympic Steel, Inc. (NASDAQ:ZEUS) Faces Market Fluctuations with Strategic...